Positive results from in vivo toxicological studies in which AEF0117 demonstrates a very favorable therapeutic index, more than 13,000 times higher than the active dose
Finalization of the development of the active ingredient and the pharmaceutical product at an advanced stage, allowing its administration within the framework of phase 3 clinical studies
Conducted an environmental risk study indicating that AEF0117 poses no risk to the environment
Non-clinical developments confirming the positive opinion of a committee of independent experts (DSMB) on the first 115 patients of the phase 2b study of AEF0117 (end of recruitment expected in Q4 2023) validating the good tolerance of AEF0117 in people suffering from cannabis addiction
To receive all AELIS FARMA financial information in real time, request it by email to [email protected]. Your registration will be immediate.